Krebs Biochemicals and Industries Q2 Results FY27 Preview: Results Date, Expectations and a Look at the Numbers
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Results
CMP Rs 55.48. Market cap Rs 120.0 crore. Q1 FY27 net profit Rs -2.48 lakh. Book value negative at Rs -75.5/share.
Track the latest Krebs Biochemicals and Industries Ltd. share price on Univest.
Krebs Biochemicals and Industries Q2 results for the quarter ended September 2026 are due in the coming weeks, and this krebs biochemicals and industries q2 results preview walks through the expected date, recent quarterly trends and valuation snapshot for Krebs Biochemicals and Industries Ltd.. This krebs biochemicals and industries q2 results preview relies only on the company’s reported historical numbers, with no invented estimates for the upcoming quarter.
Open a free demat account with Univest
Krebs Biochemicals and Industries Q2 results Date: When Will Krebs Biochemicals and Industries Announce Q2 FY27 Results?
The krebs biochemicals and industries q2 results date has not been officially announced yet. Based on the company’s historical results calendar pattern, Krebs Biochemicals and Industries Q2 results for the September 2026 quarter are typically expected in the second half of October or early November 2026. Investors tracking this q2 results date should watch for an official board meeting intimation to the exchanges, which will confirm the exact date closer to the event.
Krebs Biochemicals and Industries Q2 results Expectations for the September 2026 Quarter
Krebs Biochemicals and Industries Q2 results expectations at this stage need to be built around metrics, trends and factors rather than specific numbers, since no analyst estimates or management guidance for Q2 FY27 have been used here. The recent operating margin trend, revenue trajectory and other income pattern are the key data points investors will likely track when the q2 results 2026 are announced.
Also read – Gabriel India Q2 Results FY27 Preview
One factual observation from the company’s recent quarterly data: Chronic loss-maker, negative book value; standalone data used. This is a historical observation, not a forecast for the September 2026 quarter.
Krebs Biochemicals and Industries Q1 FY27 (June 2026 Quarter) Performance
In Q1 FY27 (June 2026), Krebs Biochemicals and Industries Ltd. reported revenue of Rs 6.98 lakh, operating profit of Rs 0.82 lakh at a margin of 11.75%, and net profit/loss of Rs -2.48 lakh on a standalone basis. These figures are the base for the sequential comparison once krebs biochemicals and industries q2 results are declared.
Krebs Biochemicals and Industries Q2 FY26 (September 2025 Quarter): The YoY Base
For year-on-year comparison, the base quarter is Q2 FY26 (September 2025), when Krebs Biochemicals and Industries Ltd. posted revenue of Rs 4.17 lakh, an operating profit/loss of Rs -2.80 lakh at a margin of -67.15%, and a net profit/loss of Rs -6.14 lakh. This Sep25 quarter is the number against which the eventual Krebs Biochemicals and Industries Q2 results will be measured on a year-on-year basis.
Krebs Biochemicals and Industries Recent Quarterly Trend: Jun25 to Jun26
| Quarter | Revenue | Operating Margin | Net Profit |
|---|---|---|---|
| Q1 FY26 (Jun25) | Rs 5.48 lakh | -38.14% | Rs -5.32 lakh |
| Q2 FY26 (Sep25) | Rs 4.17 lakh | -67.15% | Rs -6.14 lakh |
| Q3 FY26 (Dec25) | Rs 7.27 lakh | 4.13% | Rs -3.13 lakh |
| Q4 FY26 (Mar26) | Rs 6.81 lakh | -12.63% | Rs -2.48 lakh |
| Q1 FY27 (Jun26) | Rs 6.98 lakh | 11.75% | Rs -2.48 lakh |
Walking through five quarters from Jun25 to Jun26, the trend in Krebs Biochemicals and Industries’s revenue, operating margin and net profit gives a sense of the direction heading into the q2 results FY27. Investors comparing this table with the eventual September 2026 numbers will get a clearer read on whether the recent pattern is continuing or changing.
Track this stock by opening a free demat account with Univest
Key Factors to Watch Ahead of Krebs Biochemicals and Industries Q2 results
These are the metrics and trends worth tracking ahead of krebs biochemicals and industries q2 results, based only on the company’s own reported history rather than any invented projection.
Whether the company can sustain the positive operating margin of 11.75% seen in Q1 FY27 after several quarters of losses.
The revenue base remains very small in absolute terms, so percentage swings in margin can look large but reflect a low base.
Also read – Gala Precision Engineering Q2 Results FY27 Preview
Krebs Biochemicals continues to carry a negative book value per share, which investors should factor into any valuation assessment.
Any update on debt levels, working capital and the company’s ability to fund operations without further erosion of net worth.
Krebs Biochemicals and Industries Valuation Snapshot Ahead of Q2 Results FY27
Krebs Biochemicals and Industries Ltd.’s valuation ratios are not meaningful in the conventional sense. The company’s trailing PE and EPS are reported as not meaningful on a trailing loss, and ROE, PB and debt-to-equity are also not meaningful, largely because book value per share is negative (Rs -75.5 per share) and profitability has been inconsistent or negative in recent quarters. Standard valuation multiples simply do not apply in a meaningful way to a company with negative net worth.
The current market price (CMP) is Rs 55.48, with a 52-week range of Rs 38.33 to Rs 82.49 and a market capitalisation of about Rs 120.0 crore. The dividend yield stands at 0.0%.
What to Watch in Krebs Biochemicals and Industries Q2 results for Q2 FY27
Once Krebs Biochemicals and Industries Ltd. announces krebs biochemicals and industries q2 results, the immediate points of comparison will be sequential change versus the Q1 FY27 quarter and year-on-year change versus the Q2 FY26 base quarter. Investors following this krebs biochemicals and industries q2 results preview should watch the operating margin direction, any commentary accompanying the release, and whether the recent trend table shown above continues or breaks.
Get started by opening a free demat account with Univest
Conclusion
This krebs biochemicals and industries q2 results preview has been built around Krebs Biochemicals and Industries Ltd.’s reported historical quarterly data, its recent trend from Jun25 through Jun26, and its current valuation metrics, without any invented numbers for the September 2026 quarter. The exact date for Krebs Biochemicals and Industries Q2 results will only be confirmed once Krebs Biochemicals and Industries intimates its board meeting to the exchanges, and actual q2 results 2026 numbers should be read from the company’s official filings when released. This article offers no investment recommendation.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Univest Comtrade Private Limited (SEBI Research Analyst Registration No. INH000013776) does not guarantee the accuracy, completeness, or timeliness of the information provided. Investors should conduct their own research or consult a qualified financial advisor before making any investment decisions. Investments in securities are subject to market risks; please read all related documents carefully before investing.
When is the Krebs Biochemicals and Industries Q2 results date?
Ans. The krebs biochemicals and industries q2 results date has not been officially announced yet. Based on the company’s historical results calendar pattern, Krebs Biochemicals and Industries Q2 results for the September 2026 quarter are typically expected in the second half of October or early November 2026.
What was Krebs Biochemicals and Industries’s net profit in Q1 FY27?
Ans. In the June 2026 quarter (Q1 FY27), Krebs Biochemicals and Industries Ltd. reported a net profit/loss of Rs -2.48 lakh on revenue of Rs 6.98 lakh.
What is the base quarter for Krebs Biochemicals and Industries’s Q2 FY27 year-on-year comparison?
Ans. The base quarter is Q2 FY26 (September 2025), when Krebs Biochemicals and Industries Ltd. reported revenue of Rs 4.17 lakh and net profit/loss of Rs -6.14 lakh. Q2 FY27 numbers will be compared against this base once announced.
Why are PE and ROE not meaningful for Krebs Biochemicals?
Ans. Krebs Biochemicals and Industries has a negative book value per share and has been a chronic loss-maker in recent years, which is why standard ratios like PE, PB and ROE are reported as not meaningful rather than as specific numbers.
